32496-15-4

Basic information

• Product Name: 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione 4-oxide
• Synonyms: Pyrimido(5,4-e)-1,2,4-triazine-5,7(1H,6H)-dione, 3-(4-chlorophenyl)-1,6-dimethyl-, 4-oxide; Pyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-dione, 3-(4-chlorophenyl)-1,6-dimethyl-, 4-oxide
• CAS NO: 32496-15-4
• Molecular Formula: C₁₃H₁₀ClN₅O₃
• Molecular Weight: 319.7032
• Mol File: 32496-15-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 449.8°C at 760 mmHg
• Flash Point: 225.9°C
• Density: 1.61g/cm³
• Vapor Pressure: 2.77E-08mmHg at 25°C
• Refractive Index: 1.738
• CAS DataBase Reference: 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione 4-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione 4-oxide(32496-15-4)
• EPA Substance Registry System: 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione 4-oxide(32496-15-4)

Safety Data

• Hazardous Substances Data: 32496-15-4(Hazardous Substances Data)

Usage

General Description

3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione 4-oxide is a chemical compound that belongs to the pyrimidine family. Its molecular formula is C13H10N4O2Cl and it is a white solid at room temperature. It is used in the synthesis of pharmaceuticals and agrochemicals. 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione 4-oxide has potential applications in the field of medicinal chemistry and drug discovery due to its structural features and biological activities. Its unique chemical structure makes it a valuable molecule for research and development in various fields.

Upstream product

• 32502-54-8 6-(2-(4-chlorobenzylidene)-1-methylhydrazinyl)-3-methylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of β-catenin/TCF transcription

Nearly all colorectal cancers (CRCs) and varied subsets of other cancers have somatic mutations leading to β-catenin stabilization and increased β-catenin/TCF transcriptional activity. Inhibition of stabilized β-catenin in CRC cell lines arrests their growth and highlights the potential of this mechanism for novel cancer therapeutics. We have pursued efforts to develop small molecules that inhibit β-catenin/TCF transcriptional activity. We used xanthothricin, a known β-catenin/TCF antagonist of microbial origin, as a lead compound to synthesize related analogues with drug-like features such as low molecular weight and good metabolic stability. We studied a panel of six candidate Wnt/β-catenin/Tcf- regulated genes and found that two of them (Axin2, Lgr5) were reproducibly activated (9-10 fold) in rat intestinal epithelial cells (IEC-6) following β-catenin stabilization by Wnt-3a ligand treatment. Two previously reported β-catenin/TCF antagonists (calphostin C, xanthothricin) and XAV939 (tankyrase antagonist) inhibited Wnt-activated genes in a dose-dependent fashion. We found that four of our compounds also potently inhibited Wnt-mediated activation in the panel of target genes. We investigated the mechanism of action for one of these (8c) and demonstrated these novel small molecules inhibit β-catenin transcriptional activity by degrading β-catenin via a proteasome-dependent, but GSK3β-, APC-, AXIN2- and βTrCP-independent, pathway. The data indicate the compounds act at the level of β-catenin to inhibit Wnt/β-catenin/TCF function and highlight a robust strategy for assessing the activity of β-catenin/TCF antagonists.